A "good" price-to-earnings (P/E) ratio in the pharmaceutical sector typically ranges between 15 and 25, though this benchmark varies widely depending on a company's focus. Established mature pharmaceutical giants with steady, reliable cash flows often trade at lower, conservative multiples, whereas high-growth biotechnology firms and innovative drug developers command much higher P/E ratios due to anticipated future earnings growth driven by breakthrough drug pipelines.